Figure 7From: Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain Tactile (A) and thermal (B) sensory testing data for mice with established diabetes receiving either intranasal or intraperitoneal cannabidiol or SR144528 at low high dose, with comparison to non-diabetic mice receiving intranasal or intraperitoneal saline. There were no effects upon either tactile allodynia or thermal hyperalgesia development or maintenance in any group at any dose (non-matched ANOVA tests, p NS). [n = 4-10 mice in each mouse cohort for each time point] despite early intervention studies for cannabidiol demonstrating protection against development and maintenance of neuropathic pain.Back to article page